CRVL
Get informed when a big investor buys or sells
+ FollowOvervalued by 15.1% based on the discounted cash flow analysis.
| Market cap | $3.06 Billion |
|---|---|
| Enterprise Value | $2.85 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.15 |
| Beta | 0.98 |
| Outstanding Shares | 51,150,000 |
| P/E Ratio | 27.93 |
|---|---|
| PEG | 160.09 |
| Price to Sales | 3.37 |
| Price to Book Ratio | 8.66 |
| Enterprise Value to Revenue | 2.97 |
| Enterprise Value to EBIT | 26.94 |
| Enterprise Value to Net Income | 34 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 1.89%▼ 50.74% |
|---|---|
| Total Invested | $57.21M▼ 96.13% |
| Investors Holding | 76▼ 206.00% |
No data
Controls Medicare and Medicaid policy; decisions on whether to expand dental benefits under these programs represent the largest potential volume catalyst for labs.
Regulates the FDA, which provides oversight for dental devices and materials; also influences labor costs and workplace safety in labs.
Focuses on issues affecting seniors, including dental health and the affordability of dentures/prosthetics, often driving legislative interest in Medicare dental coverage.